| Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation SD Rhodes, Y He, A Smith, L Jiang, Q Lu, J Mund, X Li, W Bessler, S Qian, ... Human molecular genetics 28 (16), 2752-2762, 2019 | 77 | 2019 |
| Follicular morphology, oocyte diameter and localisation of fibroblast growth factors in the domestic dog ovary N Songsasen, A Fickes, BS Pukazhenthi, DE Wildt Reproduction in Domestic Animals 44, 65-70, 2009 | 70 | 2009 |
| Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial MJ Fisher, CS Shih, SD Rhodes, AE Armstrong, PL Wolters, E Dombi, ... Nature medicine 27 (1), 165-173, 2021 | 65 | 2021 |
| Intraspecific cone opsin expression variation in the cichlids of Lake Malawi AR Smith, L D’ANNUNZIO, AE Smith, A Sharma, CM Hofmann, ... Molecular ecology 20 (2), 299-310, 2011 | 48 | 2011 |
| Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK LS Chang, JL Oblinger, AE Smith, M Ferrer, SP Angus, E Hawley, ... PLoS One 16 (7), e0252048, 2021 | 30 | 2021 |
| PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2) E Hawley, J Gehlhausen, S Karchugina, HY Chow, D Araiza-Olivera, ... Human molecular genetics 30 (17), 1607-1617, 2021 | 18 | 2021 |
| Hedgehog signalling in bone and osteoarthritis: the role of Smoothened and cholesterol AE Smith, ES Sigurbjörnsdóttir, E Steingrimsson, S Sigurbjörnsdóttir The FEBS Journal 290 (12), 3059-3075, 2023 | 17 | 2023 |
| Ketotifen modulates mast cell chemotaxis to kit-ligand, but does not impact mast cell numbers, degranulation, or tumor behavior in neurofibromas of NF1-deficient mice CA Burks, SD Rhodes, WK Bessler, S Chen, A Smith, JR Gehlhausen, ... Molecular cancer therapeutics 18 (12), 2321-2330, 2019 | 14 | 2019 |
| Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours S Gampala, F Shah, C Zhang, SD Rhodes, O Babb, M Grimard, ... British journal of cancer 124 (9), 1566-1580, 2021 | 13 | 2021 |
| Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2 BM Wahle, ET Hawley, Y He, AE Smith, J Yuan, AR Masters, DR Jones, ... Oncotarget 9 (1), 718, 2018 | 10 | 2018 |
| Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17 JA Mund, SJ Park, AE Smith, Y He, L Jiang, E Hawley, MJ Roberson, ... Journal of Biological Chemistry 295 (29), 9948-9958, 2020 | 9 | 2020 |
| Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1 AE Armstrong, SD Rhodes, A Smith, S Chen, W Bessler, MJ Ferguson, ... Pediatric blood & cancer 67 (8), e28372, 2020 | 8 | 2020 |
| A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas JR Gehlhausen, E Hawley, BM Wahle, Y He, D Edwards, SD Rhodes, ... Human Molecular Genetics 28 (4), 572-583, 2019 | 8 | 2019 |
| Spatial gene-expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression DK Mitchell, B Burgess, EE White, AE Smith, EA Sierra Potchanant, ... Clinical Cancer Research 30 (5), 1038-1053, 2024 | 5 | 2024 |
| Irradiation of Nf1 mutant mouse models of spinal plexiform neurofibromas drives pathologic progression and decreases survival D Laurent, AE Smith, WK Bessler, M Mendonca, H Chin-Sinex, ... Neuro-Oncology Advances 3 (1), vdab063, 2021 | 5 | 2021 |
| Combined CDK4/6 and ERK1/2 inhibition enhances antitumor activity in NF1-associated plexiform neurofibroma AC Flint, DK Mitchell, SP Angus, AE Smith, W Bessler, L Jiang, H Mang, ... Clinical Cancer Research 29 (17), 3438-3456, 2023 | 4 | 2023 |
| A comparison of urinary hormone profiles with fecal extract hormone profiles of Equus ferrus przewalskii A Fickes The Ohio State University, 2007 | 2 | 2007 |
| EXTH-13. Reduction of tumor burden and hearing loss with a multiple receptor tyrosine kinase inhibitor brigatinib in a genetically engineered mouse model of neurofibromatosis … A Smith, W Bessler, L Jiang, X Li, Q Lu, J Yuan, Y He, A Masters, D Jones, ... Neuro-oncology 20 (Suppl 6), vi87, 2018 | 1 | 2018 |
| Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma AC Flint, DK Mitchell, SP Angus, AE Smith, W Bessler, L Jiang, H Mang, ... Clinical Cancer Research 30 (9), 1992-1992, 2024 | | 2024 |
| Deciphering the Immune Microenvironment of NF1-associated Peripheral Nerve Sheath Tumors: Identifying Early Biomarkers of Disease Progression and Malignant Transformation J Mukherji, D Mitchell, E White, B Burgess, A Smith, E Albright, J Khan, ... Proceedings of IMPRS 6 (1), 2023 | | 2023 |
D Wade ClappIndiana University, Department of PediatricsVerified email at iu.edu
